|
|
Protective effects of nicotine on gamma-aminobutyric
acid neurons and dopaminergic neurons in mice with Parkinson disease |
Lei FU MD 1, Dezheng GONG BM 1, Yan PENG 1, Dongmei WANG BM 1, Hong XU 1, Yue LI MD 2, Dengqin YU BS 2, Yanhui FENG MD 2, Shengming YIN PhD 2, Jin GONG 3, Yiping SUN PhD 4, |
1.Lab of Physiological
Function, College of Basic Medicine, Dalian Medical University, Dalian
116044, China; 2.Department of Physiology,
College of Basic Medicine, Dalian Medical University, Dalian 116044,
China; 3.Department of Anatomy,
College of Basic Medicine, Dalian Medical University, Dalian 116044,
China; 4.Lab of Physiological
Function, College of Basic Medicine, Dalian Medical University, Dalian
116044, China;Department of Physiology,
College of Basic Medicine, Dalian Medical University, Dalian 116044,
China; |
|
|
Abstract This study aimed to investigate the protective effect of nicotine on dopaminergic neurons and its mechanisms in mice with Parkinson disease (PD) induced by 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP). C57BL/6J mice were injected with MPTP for 8 days to establish a PD model. Nicotine was given for 10 days in the nicotine therapeutic group. Animals were examined behaviorally with the pole test and traction test. Tyrosine hydroxylase (TH) and γ-aminobutyric acid (GABA) were determined by using the immunocytochemistry (ICC) method. The ultrastructural changes of the caudate nucleus (CN) were observed under electron microscopy. The results showed that pretreatment with nicotine could improve the dyskinesia of PD mice markedly. Simultaneously, TH-positive (P < 0.01) neurons and GABA-positive (P < 0.05) neurons in the nicotine therapeutic group were significantly more than those in the model group. The ultrastructural injury of the nicotine therapeutic group was also ameliorated. Nicotine has protective effects on the γ-aminobutyric acid neurons and dopaminergic neurons in the MPTP-treated mice.
|
Keywords
Parkinson disease
nicotine
dopaminergic neuron
gamma-aminobutyric acid neuron
|
Issue Date: 05 September 2009
|
|
|
Dauer W, Przedborski S. Parkinson’s disease:mechanisms and models. Neuron, 2003, 39(6): 889―909
doi: 10.1016/S0896-6273(03)00568-3
|
|
Carr L A, Rowell P P. Attenuation of 1-methyl-4-phenyl-1,2, 3, 6-tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacology, 1990, 29(3): 311―314
doi: 10.1016/0028-3908(90)90019-N
|
|
Jansen A M, Fuxe K, Goldstein M. Differential effects of acute and chronic nicotine treatmenton MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)induced degenerationof nigrostriatal dopamine neurons in the black mouse. Clin Investig, 1992, 70(3,4): 232―238
|
|
Parain K, Marchand V, Dumery B, Hirsch E. Nicotine,but not cotinine, partially protects dopaminergic neurons againstMPTP-induced degeneration in mice. BrainRes, 2001, 890(2): 347―350
doi: 10.1016/S0006-8993(00)03198-X
|
|
Maggio R, Riva M, Vaglini F, Fronai F, Molteni R, Armogida M, Racagni G, Corsini G U. Nicotine prevents experimentalparkinsonism in rodents and induces striatal increase of neurotrophicfactors. J Neurochem, 1998, 71(6): 2439―2446
|
|
Maggio R, Riva M, Vaglini F, Fronai F, Racagni G, Corsini G U. Striatal increase of neurotrophic factors as a mechanismof nicotine protection in experimental parkinsonism. J Neural Transm, 1997, 104(10): 1113―1123
doi: 10.1007/BF01273324
|
|
Belluardo N, Blum M, Mudo G, Andbjer B, Fuxe K. Acute intermittent nicotinetreatment produces regional increases of basic fibroblast growth factormessenger RNA and protein in the tel- and diencephalon of the rat. Neuroscience, 1998, 83(3): 723―740
doi: 10.1016/S0306-4522(97)00323-0
|
|
Arai N, Misugi K, Goshima Y, Misu Y. Evaluationof a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treatedC57 black mouse model for parkinsonism. Brain Res, 1990, 515(1,2): 57―63
|
|
Jakowec M W, Petzinger G M. 1-methyl-4-phenyl-1, 2, 3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasison mice and nonhuman primates. Comp Med, 2004, 54(5): 497―513
|
|
Fredriksson A, Archer T. MPTP-induced behaviouraland biochemical deficits: a parametric analysis. J Neural Transm Park Dis Dement Sect, 1994, 7(2): 123―132
doi: 10.1007/BF02260967
|
|
Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord, 1998, 13(Suppl 1): 35―38
|
|
Dawson T, Mandir A, Lee M. Animal models of PD: pieces of the same puzzle? Neuron, 2002, 35(2): 219―222
doi: 10.1016/S0896-6273(02)00780-8
|
|
Sedelis M, Hofele K, Auburger G W, Morgan S, Huston J P, Schwarting R K. MPTP susceptibility in the mouse: behavioral, neurochemical,and histological analysis of gender and strain differences. Behav Genet, 2000, 30(3): 171―182
doi: 10.1023/A:1001958023096
|
|
Beal M F. Experimental models of parkinson’s disease. Nat Rev Neurosci, 2001, 2(5): 325―334
doi: 10.1038/35072550
|
|
Yu X, Sun L, Luo X, Xu Z, An L. Investigation of the neuronal death mode induced by glutamatetreatment in serum-, antioxidant-free primary cultured cortical neurons. Brain Res Dev Brain Res, 2003, 145(2): 263―268
doi: 10.1016/j.devbrainres.2003.08.008
|
|
Limatola C, Lauro C, Catalano M, Ciotti M T, Bertollini C, Di Angelantonio S, Ragozzino D, Eusebi F. Chemokine CX3CL1 protectsrat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol, 2005, 166(1,2): 19―28
|
|
Kikuchi S, Kim S U. Glutamate neurotoxicity inmesencephalic dopaminergic neurons in culture. J Neurosci Res, 1993, 36(5): 558―569
doi: 10.1002/jnr.490360508
|
|
Plaitakis A, Shashidharan P. Glutamate transport and metabolismin dopaminergic neurons of substantia nigra: implications for thepathogenesis of Parkinson's disease. JNeurol, 2000, 247 (Suppl 2): II25―35
doi: 10.1007/PL00007757
|
|
Konitsiotis S, Blanchet P J, Verhagen L, Lamers E, Chase T N. AMPA receptor blockade improveslevodopa-induced dyskinesia in MPTP monkeys. Neurology, 2000, 54(8): 1589―1595
|
|
Hadj Tahar A, Gregoire L, Darre A, Bélanger N, Meltzer L, Bédard P J. Effect of a selective glutamate antagoniston L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis, 2004, 15(2): 171―176
doi: 10.1016/j.nbd.2003.10.007
|
|
Herrero M T, Barcia C, Navarro J M. Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst, 2002, 18(8): 386―404
doi: 10.1007/s00381-002-0604-1
|
|
Wichmann T, Kliem M A, DeLong M R. Antiparkinsonian and behavioral effects of inactivationof the substantia nigra pars reticulata in hemiparkinsonian primates. Exp Neurol, 2001, 167(2): 410―424
doi: 10.1006/exnr.2000.7572
|
|
Winkler C, Bentlage C, Nikkhah G, Samii M, Björklund A. Intranigral transplants ofGABA-rich striatal tissue induce behavioral recovery in the rat Parkinsonmodel and promote the effects obtained by intrastriatal dopaminergictransplants. Exp Neurol, 1999, 155(2): 165―186
doi: 10.1006/exnr.1998.6916
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|